Electronics Obsolescence and Counterfeit-Risk Adviser — Medical Imaging

The mandate

The board’s standing question is how to preserve fifteen-year service obligations for imaging platforms whose processors, converters, memories and power components are reaching end of life faster than validated redesigns can be introduced. Procurement has used independent brokers to bridge shortages, quality teams reject incomplete provenance, and service regions cannibalise returned boards. Directors need an evidence-based portfolio choice among lifetime buys, qualified alternates, redesign and managed equipment retirement.

The adviser contributes four days monthly, attends quarterly Stockholm board sessions and joins the planned Lund, Munich and Singapore reviews. Each month, one high-consequence component family is examined from manufacturer notice through installed-base demand, storage, authenticity, design dependence and regulatory change. Urgent written counsel is available within three working days before a lifetime-buy deadline, without turning the adviser into sourcing execution or lot-release management.

The appointment lasts eight months and may renew once for up to three months if a critical redesign validation or manufacturer allocation remains unresolved. Renewal requires a committee minute stating the residual board decision, fixed cadence and refreshed conflicts. It cannot become continuing supplier surveillance, component engineering or purchasing approval after the portfolio plan has accountable internal owners.

The adviser has no line authority and assumes no executive responsibility for procurement, quality release, regulatory submissions, redesign or service decisions. Engineering, quality and supply executives retain those authorities. The adviser may challenge demand, authenticity evidence and redesign timing, but cannot approve broker material, sign a deviation, place a lifetime buy or determine whether a medical system remains in clinical service.

Conflicts include authorised distributors, independent brokers, test laboratories, component manufacturers, contract manufacturers, redesign houses and aftermarket providers. Employment, board positions, commissions, equity, referral fees and paid technical reviews must be disclosed. A new relationship with a proposed broker or alternate-component supplier during the term requires prior committee approval and may make continued advice untenable.

Why the board wants this voice

Obsolescence decisions convert uncertain installed-base demand into irreversible inventory or redesign commitments. Shortage pressure can also make weak provenance look commercially necessary, while excessive caution may strand essential clinical equipment. Independent counsel helps the board balance patient continuity, technical authenticity, regulatory evidence and working capital without normalising grey-market risk.

What you will own

• Challenge installed-base demand using service mortality, regional usage, repair yield, cannibalisation, retirement and regulatory support assumptions.
• Examine component criticality across safety function, software dependence, calibration, cybersecurity, thermal behaviour and redesign complexity.
• Test provenance evidence for authorised channels, broker chains, date codes, storage history, remarking, die authenticity and lot consistency.
• Compare lifetime buy, alternate qualification, board redesign, emulation and managed product retirement through scenario economics.
• Advise sampling and destructive-analysis depth by consequence, source confidence, population size and false-acceptance cost.
• Review storage, preservation, retest and allocation controls needed to keep long-held electronic inventory genuinely usable.
• Leave the board a component decision ledger, capital exposures, redesign gates, supplier challenges and monitored exhaustion triggers.

Candidate qualifications

• Advised long-life electronics continuity for medical, aerospace, defence, rail or industrial systems with regulated change control.
• Can evidence a broker lot rejected or bounded after provenance and physical analysis contradicted commercial assurances.
• Understands component lifecycle notices, authenticity testing, storage degradation, alternate qualification and electronics redesign dependencies.
• Has modelled lifetime-buy demand without treating current service consumption as a stable long-term forecast.
• Worked across quality, regulatory, service, engineering and procurement when supply urgency challenged release discipline.
• Maintained independence amid distributor incentives, broker commissions, laboratory referrals and redesign-provider interests.

Non-negotiables

• Will attend every Stockholm, Lund, Munich and Singapore session in the advisory calendar.
• Holds no undisclosed commission, equity or referral relationship with a broker or test laboratory.
• Accepts no authority to release parts, place orders, approve redesigns or decide continued clinical use.
• Brings direct counterfeit and long-life electronics judgment beyond generic supply-chain risk or procurement strategy.

1. 49 words maximum. Which authenticity clue most changed a decision on urgently needed broker-sourced electronics?
2. 49 words maximum. How would you distinguish a prudent lifetime buy from inventory created by weak demand assumptions?
3. 49 words maximum. Which distributor, broker, laboratory or redesign relationship requires disclosure here?